Antimicrobial Pharmacodynamics Overview

Principles

Definition

Antimicrobial pharmacodynamics is the study of the relationship between the concentration of an antimicrobial agent over time at the site of infection and its resulting microbiological effect. This research field investigates how drug exposure parameters correlate with bacterial killing or inhibition, providing a scientific basis for optimizing dosing regimens to enhance clinical outcomes and mitigate the development of resistance.

Ontological type

Key PK/PD indices

Dose optimization strategies

Mechanisms of bacterial killing

Key developments

Key Figures

Host-centered PK Integration era

Ernest Jawetz [1] was associated with University of California, San Francisco [3] and Stanford University [4] during this era. Jawetz [1] argued for antibiotic synergy, as shown by The Combined Action of Penicillin with Streptomycin or Chloromycetin on Enterococci in Vitro [6] and Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action [7], a viewpoint that underscored how combination strategies and exposure-driven dosing emerged from tissue-penetration and host-context observations. J. B. Gunnison [2] was based at University of California, San Francisco [3] and University of Washington [5] during this era. Gunnison [2], along with The Combined Action of Penicillin with Streptomycin or Chloromycetin on Enterococci in Vitro [6] and Studies on antibiotic synergism and antagonism: a scheme of combined antibiotic action [7], helped advance understanding of antibiotic synergy and combination therapy in host-centered pharmacodynamics, illustrating the practical translation of tissue-level exposure concepts into dosing strategies.

Foundational PK/PD Frameworks era

William A. Craig [1], affiliated with University of Washington [3] and University of Wisconsin–Madison [4], helped shape early PK/PD thinking in this era. His key contributions include Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection Models [7], The Postantibiotic Effect [8], and Postantibiotic effects [9], which collectively linked drug exposure to bacterial killing and resistance suppression in this era. Stephen H. Zinner [2], affiliated with Harvard University [5] and Northwestern University [6], contributed to foundational PK/PD work. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model [10] illustrated how dosing regimens and two-compartment models could delineate exposure targets for optimizing antimicrobial therapy in this era.

Precision PK/PD Implementation era

Michael J. Rybak [1] is a leading antimicrobial pharmacodynamics researcher whose work spans Rockefeller University [3] and Harvard University [4] in this era, contributing to the development of precision PK/PD approaches to antimicrobial therapy. His key contributions in this era include integrating PK/PD principles into clinical practice through the IDSA guidelines for MRSA treatment (2011) [6] and their executive summary [7], and advancing understanding of vancomycin resistance via agr-focused research [8] and a viewpoint arguing vancomycin is not obsolete in certain infections [9]. Barbara E. Murray [2] has held positions at Harvard University [4] and Johns Hopkins University [5] during this era. Her contributions include co-authoring and guiding MRSA treatment guidelines through IDSA work [6] and executive summaries [7], reflecting her role in precision PK/PD implementation, and she contributed to early resistance work via agr studies [8] and advocacy that vancomycin remains clinically relevant [9].